OncoMatch/Clinical Trials/NCT05701488
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Is NCT05701488 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Durvalumab and Tremelimumab for resectable hepatocellular carcinoma.
Treatment: Durvalumab · Tremelimumab · SIRT — The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IA, IB, II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any prior treatment for hcc
Lab requirements
Blood counts
hemoglobin ≥ 9.0 g/dl; absolute neutrophil count (anc) ≥ 1,000 /mcl; platelets ≥ 80,000 /mcl
Kidney function
measured creatinine clearance > 40 ml/min by 24-hour urine collection, or calculated creatinine clearance (cl) > 40 ml/min by the cockcroft-gault formula
Liver function
total bilirubin ≤ 2.0 mg/dl; ast (sgot) and alt (sgpt) ≤ 2.5 × institutional upper limit of normal (uln); preserved liver function (child a)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center · Los Angeles, California
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05701488 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IA or IB or II or IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages